10-K: Indaptus Therapeutics Reports 2024 Results and Provides Business Update

Indaptus Therapeutics, a clinical-stage biotechnology company, released its 2024 financial results and provided an update on its ongoing clinical development programs, including the Phase 1 trial of Decoy20 and a planned combination study with BeiGene's tislelizumab.

Summary

• Indaptus Therapeutics is a clinical-stage biotechnology company focused on developing anti-cancer and anti-viral immunotherapies.
• The company's lead candidate, Decoy20, is currently in a Phase 1 clinical trial for advanced solid tumors.
• In 2024, Indaptus enrolled more than 20 patients in the weekly dosing part of the Phase 1 trial and observed early signs of potential benefits with some patients showing stable disease.
• Indaptus plans to initiate a combination study of Decoy20 with BeiGene's tislelizumab in 2025.
• The company received clinical trial authorization from Health Canada to expand its U.S. clinical trial to Canadian sites in February 2025.
• Indaptus reported a net loss of approximately $15.0 million for the year ended December 31, 2024, and had approximately $5.8 million in cash and cash equivalents as of December 31, 2024.
• The company believes its current cash resources will fund operations into the second quarter of 2025 and will need to raise additional capital.
• In February 2025, Indaptus entered into a Standby Equity Purchase Agreement with Yorkville for up to $20.0 million of its common stock.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positive developments in the clinical trial program and plans for a combination study, the company's financial situation raises concerns about its ability to continue as a going concern. The need for additional capital and the reported net loss contribute to a negative sentiment.

Positives

• Decoy20 has shown early signs of potential benefits with some patients showing stable disease in the Phase 1 clinical trial.
• The planned combination study with BeiGene's tislelizumab builds on preclinical results where Decoy20, combined with a PD-1 inhibitor, demonstrated high tumor eradication rates and established immunological memory.
• The clinical trial authorization from Health Canada allows Indaptus to expand its clinical trial to Canadian sites.
• The company has a patented technology composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria.

Negatives

• Indaptus reported a net loss of approximately $15.0 million for the year ended December 31, 2024.
• The company had approximately $5.8 million in cash and cash equivalents as of December 31, 2024.
• Indaptus believes its current cash resources will fund operations into the second quarter of 2025 and will need to raise additional capital.
• The company has identified conditions and events that raise substantial doubt regarding its ability to continue as a going concern.

Risks

• The company's future operations are dependent upon the successful entry into collaborations, strategic alliances, or license agreements with third parties and/or on the identification and successful completion of equity or debt financing.
• Clinical and preclinical development involves lengthy and expensive processes with uncertain outcomes.
• The company may expend its limited resources to pursue a limited number of research programs, product candidates and specific indications and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
• The company relies on third parties to conduct its preclinical studies and clinical trials and perform other tasks.
• The company currently relies on third parties for the manufacture of its product candidates during clinical development, and expect to continue to rely on third parties for the foreseeable future.
• The successful commercialization of Decoy20 or any future product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies.
• The market price of the company's common stock is volatile and you may sustain a complete loss of your investment.

Future Outlook

Indaptus believes its current cash resources will fund operations into the second quarter of 2025 and will need to raise additional capital. The company plans to initiate a combination study of Decoy20 with BeiGene's tislelizumab in 2025 and expand its clinical trial to Canadian sites.

Management Comments

• We are working to increase the number of trial sites to accelerate patient enrollment and data collection.
• We intend to seek approval from the FDA to initiate the Combination Study, which is anticipated to begin in 2025.

Industry Context

The announcement highlights the ongoing efforts in the biotechnology industry to develop novel immunotherapies for cancer, with a focus on combination therapies and expanding clinical trials to new regions.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the document does mention Amgen, AstraZeneca plc, BMS, Genentech, Inc., GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG, Pfizer Inc., Roche Holding Ltd and Sanofi S.A. as competitors.
• These companies are developing immunotherapeutics which may have potential to be used in concert with Decoy20 and in this regard, we view them as potentially complimentary.

Related Party Transactions

• One of the November 2024 Purchasers was our Chief Executive Officer, who purchased 42,553 shares and November 2024 Warrants to purchase 42,553 shares, or the Affiliate Securities, at the same price and upon the same terms as the other November 2024 Purchasers.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be affected by potential delays or reductions in research and development programs.
• Patients could benefit from the development of new cancer immunotherapies.
• Suppliers and creditors may be impacted by the company's financial condition and ability to meet its obligations.

Next Steps

• Advance to the expansion portion of the Phase 1 clinical trial for Decoy20.
• Expand the bacterial product platform to target additional types of cancer, as well as additional infectious diseases.
• Seek regulatory approvals for any product candidates that successfully complete clinical trials.

Key Dates